BTIG analyst Ryan Zimmerman maintains Organogenesis Hldgs (NASDAQ:ORGO) with a Buy and lowers the price target from $10 to $4.
BTIG Maintains Buy on Organogenesis Hldgs, Lowers Price Target to $4
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.